Cargando…

Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients

This study investigated whether or not vitamin D and calcium supplementation affected bone metabolism and bone mineral density (BMD) over a period of four years of denosumab therapy in patients with primary osteoporosis. Patients were divided into a denosumab monotherapy group (22 cases) or a denosu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Takako, Nakamura, Yukio, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872690/ https://www.ncbi.nlm.nih.gov/pubmed/29495518 http://dx.doi.org/10.3390/nu10030272

Ejemplares similares

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis
por: Nakamura, Yukio, et al.
Publicado: (2017)

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2018)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series
por: Kobayashi, Tsukasa, et al.
Publicado: (2018)

Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2018)

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2018)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2019)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Efficacy of denosumab therapy for a 12-year-old female patient with Williams syndrome with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2021)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
por: Sone, Teruki, et al.
Publicado: (2017)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis
por: Stumpf, U., et al.
Publicado: (2021)

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
por: Nakamura, Yukio, et al.
Publicado: (2015)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study
por: Hattori, Kyosuke, et al.
Publicado: (2019)

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
por: Yamaguchi, Yuta, et al.
Publicado: (2020)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vvu3njd7kkltbdm2nfqth958r2